Severe bout of cutaneous psoriasis in a patient with psoriasic arthritis undergoing treatment with infliximab [2]

Clinical and Experimental Rheumatology

Volumn 25, Issue 4, 2007, Pages 659-

  Uriarte Itzazelaia, E ^a   Hernando, I ^a   Prada, A ^a   Alonso, A ^a  

^a HOSPITAL DE CRUCES   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHISTAMINIC AGENT; EMOLLIENT AGENT; INFLIXIMAB; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; STEROID;

ADULT; CASE REPORT; CLINICAL FEATURE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; HUMAN; LABORATORY TEST; LETTER; MALE; PRIORITY JOURNAL; PRURITUS; PSORIASIS; PSORIATIC ARTHRITIS; SKIN BIOPSY;

ADULT; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; ARTHRITIS, PSORIATIC; HUMANS; MALE; PSORIASIS;

EID: 34648833683     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Letter

References (12)

1. ANTONI CE, KAVANAUGH A, KIRKHAM B et al.: Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis. Arthritis Rheum 2005; 52: 1227-36.
2. CHAUDHARI U, ROMANO P, MULCAHY LD et al.: Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: A randomised trial. Lancet 2001; 357: 1842-47.
3. SFIKAKIS PP, ILIOPOULOS A, ELEZOGLOU A et al.: Psoriasis induced by anti-tumor necrosis factor therapy. Arthritis Rheum 2005; 52: 2513-8.
4. DEREURE O, GUILLOT B, JORGENSEN C, COHEN JD, COMBES B, GUILHOU JJ: Psoriatic lesions induced by antitumour necrosis factor-α treatment; two cases. Br J Dermatol 2004; 150: 506-25.
5. VEREA, DEL POZO MM, YEBRA-PIMENTEL J, PORTA A, FONSECA E: Psoriasiform eruption induced by infliximab. Ann Pharmacother 2004; 38: 54-7.
6. THURBER M, FEASEL A, STROEHLEIN J, HYMES SR: Pustular psoriasis induced by infliximab. J Drugs Dermatlo 2004; 3: 439-40.
7. KARY S, WORM M, Fritz J et al.: New onset or aggravation of psoriatic skin lesions in patients with definite rheumatoid arthritis under treatment with TNF-α antagonists: Report of eight cases [abstract]. EUROPEAN LEAGUE AGAINST RHEUMATISM: Annual European Congress of Rheumatology, Berlin, Germany, June 9-12, 2004. Abstract no. FRIO095. URL: www.eular.org.
8. HAIBEL H, RUDWALEIT M, STRASSER C, SPILLER I, DORNER T, SIEPER J: Unexpected new onset or exacerbation of psoriasis in treatment of active ankylosing spondytitis with TNF-α-blocking agents; four case reports [abstract]. EUROPEAN LEAGUE AGAINST RHEUMATISM: Annual European Congress of Rheumatology, Berlin, Germany, June 9-12, 2004 Abstract no. SAT006 1. URL: www.wular.org.
9. BAETEN D, KRUITHOF E, Van den BOSCH F et al.: Systematic safety follow up in a cohort of 107 patients with spondyloarthropathy treated with infliximab: A new perspective on the role of host defence in the pathogenesis of the disease? Ann Rheum Dis 2003; 62: 829-34.
10. CAPON F, TREMBATH RC, BARKER JNWN: An update on the genetics of psoriasis. Dermatol Clin 2004; 22: 239-47.
11. BOS JD, DE RIE MA, TEUNISSEN MB, PISKIN G: Psoriasis: dysregulation of innate immunity. Br J Dermatol 2004; 152: 1099-107.
12. GRIFFITHS CEM, IACCARINO L, NALDI L: Psoriasis and psoriatic arthritis: Immunological aspects and therapeutic guidelines. Clin Exp Rheumatol 2006; 24: S-72-S-78.